These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 28167798

  • 1. Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.
    Droog M, Nevedomskaya E, Dackus GM, Fles R, Kim Y, Hollema H, Mourits MJ, Nederlof PM, van Boven HH, Linn SC, van Leeuwen FE, Wessels LF, Zwart W.
    Proc Natl Acad Sci U S A; 2017 Feb 21; 114(8):E1316-E1325. PubMed ID: 28167798
    [Abstract] [Full Text] [Related]

  • 2. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
    Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M, Schuurman K, Gradowska P, Hauptmann M, Dackus G, Hollema H, Mourits M, Nederlof P, van Boven H, Linn SC, Wessels L, van Leeuwen FE, Zwart W.
    Cancer Res; 2016 Jul 01; 76(13):3773-84. PubMed ID: 27197147
    [Abstract] [Full Text] [Related]

  • 3. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
    Notas G, Pelekanou V, Kampa M, Alexakis K, Sfakianakis S, Laliotis A, Askoxilakis J, Tsentelierou E, Tzardi M, Tsapis A, Castanas E.
    Mol Oncol; 2015 Nov 01; 9(9):1744-59. PubMed ID: 26115764
    [Abstract] [Full Text] [Related]

  • 4. Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.
    Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.
    Oncotarget; 2016 Jun 07; 7(23):33901-18. PubMed ID: 27129152
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I, Girault I, Urbain E, Tozlu S, Lidereau R.
    Breast Cancer Res; 2004 Jun 07; 6(3):R252-63. PubMed ID: 15084249
    [Abstract] [Full Text] [Related]

  • 8. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
    Motomura K, Ishitobi M, Komoike Y, Koyama H, Nagase H, Inaji H, Noguchi S.
    Oncology; 2010 Jun 07; 79(1-2):55-61. PubMed ID: 21071990
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
    Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA.
    Breast Cancer Res Treat; 2015 Nov 07; 154(2):225-37. PubMed ID: 26487496
    [Abstract] [Full Text] [Related]

  • 11. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
    van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Forsse D, Witteveen PO, Galaal K, van Ginkel A, Bignotti E, Weinberger V, Sweegers S, Kroep JR, Cabrera S, Snijders MPLM, Inda MA, Eriksson AGZ, European Network for Individualized Treatment in Endometrial Cancer, Krakstad C, Romano A, van de Stolpe A, Pijnenborg JMA.
    Am J Obstet Gynecol; 2021 Oct 07; 225(4):407.e1-407.e16. PubMed ID: 34019887
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM, Al-Dhaheri M, Dong Y, Ip C, Jones FE, Rowan BG.
    Mol Cancer Ther; 2005 Aug 07; 4(8):1239-49. PubMed ID: 16093440
    [Abstract] [Full Text] [Related]

  • 14. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M, Jukić S, Ilić-Forko J, Babić D, Uzarević B, Petrovecki M, Suchanek E, Skrablin S, Dotlić S, Marusić M.
    Gynecol Oncol; 1999 Mar 07; 72(3):331-6. PubMed ID: 10053103
    [Abstract] [Full Text] [Related]

  • 15. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J, Alayev A, Berman AY, Fornander T, Nordenskjöld B, Holz MK, Stål O.
    Breast Cancer Res Treat; 2018 Feb 07; 168(1):17-27. PubMed ID: 29128895
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA.
    Endocr Relat Cancer; 2006 Dec 07; 13(4):1121-33. PubMed ID: 17158758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.